OYSTER POINT PHARMA INC (OYST) Stock Price, Quote, News and Overview
NASDAQ:OYST - Nasdaq - US69242L1061 - Common Stock - Currency: USD
OYST Quote, Performance and Key Statistics
11.17
+0.02 (+0.18%)
The current stock price of OYST is 11.17 USD. In the past month the price decreased by -0.27%. In the past year, price decreased by -38.83%.
OYST Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About OYST
Company Profile
Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The company is headquartered in Princeton, New Jersey and currently employs 303 full-time employees. The company went IPO on 2019-10-31. The firm is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The firm's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. The company is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.
Company Info
OYSTER POINT PHARMA INC
202 Carnegie Center, Suite 106
Princeton NEW JERSEY 08540 US
CEO: Jeffrey Nau
Employees: 303
Company Website: https://oysterpointrx.com/
Phone: 16093829032.0
OYSTER POINT PHARMA INC / OYST FAQ
What is the stock price of OYSTER POINT PHARMA INC today?
The current stock price of OYST is 11.17 USD. The price increased by 0.18% in the last trading session.
What is the ticker symbol for OYSTER POINT PHARMA INC stock?
The exchange symbol of OYSTER POINT PHARMA INC is OYST and it is listed on the Nasdaq exchange.
On which exchange is OYST stock listed?
OYST stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OYSTER POINT PHARMA INC stock?
10 analysts have analysed OYST and the average price target is 28.05 USD. This implies a price increase of 151.12% is expected in the next year compared to the current price of 11.17. Check the OYSTER POINT PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OYSTER POINT PHARMA INC worth?
OYSTER POINT PHARMA INC (OYST) has a market capitalization of 299.85M USD. This makes OYST a Micro Cap stock.
How many employees does OYSTER POINT PHARMA INC have?
OYSTER POINT PHARMA INC (OYST) currently has 303 employees.
What are the support and resistance levels for OYSTER POINT PHARMA INC (OYST) stock?
OYSTER POINT PHARMA INC (OYST) has a support level at 11.13 and a resistance level at 11.2. Check the full technical report for a detailed analysis of OYST support and resistance levels.
Is OYSTER POINT PHARMA INC (OYST) expected to grow?
The Revenue of OYSTER POINT PHARMA INC (OYST) is expected to grow by 55.43% in the next year. Check the estimates tab for more information on the OYST EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy OYSTER POINT PHARMA INC (OYST) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OYST, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OYST, evaluating the profitability, health, valuation and growth aspects
- OYSTER POINT PHARMA INC (OYST) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OYSTER POINT PHARMA INC (OYST) Sales and EPS estimates to see what analysts future expectations are.
- OYSTER POINT PHARMA INC (OYST) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OYSTER POINT PHARMA INC (OYST) Insider and Institutional Ownership to learn about the owners and their transactions.
- OYSTER POINT PHARMA INC (OYST) Stock Chart to make your own analysis
- OYSTER POINT PHARMA INC (OYST) Latest news and press-releases to stay up to date.
Does OYSTER POINT PHARMA INC (OYST) stock pay dividends?
OYST does not pay a dividend.
When does OYSTER POINT PHARMA INC (OYST) report earnings?
OYSTER POINT PHARMA INC (OYST) will report earnings on 2023-02-22.
What is the Price/Earnings (PE) ratio of OYSTER POINT PHARMA INC (OYST)?
OYSTER POINT PHARMA INC (OYST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.65).
OYST Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to OYST. When comparing the yearly performance of all stocks, OYST is one of the better performing stocks in the market, outperforming 95.5% of all stocks.
OYST Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OYST. Both the profitability and financial health of OYST have multiple concerns.
OYST Financial Highlights
Over the last trailing twelve months OYST reported a non-GAAP Earnings per Share(EPS) of -6.65. The EPS decreased by -113.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OYST Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to OYST. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -66.47% and a revenue growth 55.43% for OYST